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ABSTRACT 16 
 17 
Liposomes are lipid based bilayer vesicles that can encapsulate, deliver and release low-soluble drugs and small 18 
molecules to a specific target site in the body. They are currently exploited in several nanomedicine formulations. 19 
However, their development and application is still limited by expensive and time-consuming process development and 20 
production methods. Therefore, to exploit these systems more effectively and support the rapid translation of new 21 
liposomal nanomedicines from bench to bedside, new cost-effective and scalable production methods are needed. We 22 
present a continuous process flow system for the preparation, modification and purification of liposomes which offers lab-23 
on-chip scale production. The system was evaluated for a range of small vesicles (below 300 nm) varying in lipid 24 
composition, size and charge; it offers effective and rapid nanomedicine purification with high lipid recovery (>98%) 25 
combined with effective removal of non-entrapped drug (propofol >95% reduction of non-entrapped drug present) or 26 
protein (ovalbumin >90% reduction of OVA present) and organic solvent (ethanol >95% reduction) in less than 4 27 
minutes. The key advantages of using this bench-top, rapid, process development tool are the flexible operating 28 
conditions, interchangeable membranes and scalable high-throughput yields, thereby offering simultaneous 29 
manufacturing and purification of nanoparticles with tailored surface attributes. 30 
 31 
Introduction 32 
 33 
Liposomes are a well-established formulation strategy to improve drug delivery and enhance therapeutic 34 
outcomes for a range of drugs, such as pharmaceuticals, biopharmaceuticals, and vaccines. Due to their 35 
bilayer vesicle structure, which is akin to natural cells, liposomes are able to incorporate drugs both within 36 
their aqueous core and their lipidic bilayers. Through such means, the pharmacokinetics of a drug can be 37 
controlled and dictated by the liposomal delivery system rather than the drug attributes. This has allowed the 38 
development of a range of clinically approved liposome-based medicines including DOXIL/Caelyx® 39 
(doxorubicin), AmBisome® (amphotericin B) and Daunoxome® (daunorubicin), which when combined have 40 
an annual market revenue of approximately $100 million. However, despite these advantages, their wider 41 
application is limited by their complex and costly production requirements. Currently, manufacturing methods 42 
include the use of solvent injection, reverse-phase evaporation and emulsification methods1. Such methods 43 
have the disadvantage of involving multi-step processes, often adopt large amounts of organic solvents and 44 
are limited to batch-release processes.  Furthermore, a crucial attribute to an effective liposomal drug system 45 
is the vesicle size range, which can be controlled the production method, e.g. sonication (20-40 nm)2, 46 
extrusion (70 - 415 nm)3 or high-pressure homogenisation (20 - 140 nm)4; and, more recently, microfluidic 47 
mixing (20 - 80 nm)5, 6 or flow focusing (50 - 150 nm)7. Upon administration, the pharmacokinetic profile and 48 
fate of liposomes is dictated by their size and therefore controlling particle size and polydispersity (PDI) is a 49 
key issue in their manufacturing and a key parameter in the product specifications. To produce liposomes in 50 
a controlled size range, downsizing through extrusion or homogenisation is often adopted. This adds further 51 
steps to the manufacturing process and exposes the liposomes and drug constituents to harsh and 52 
potentially detrimental processing conditions. To address these issues, and allow the wider adoption of 53 
liposomal systems to improve health-care, new methods in liposome manufacture are therefore required. 54 
 55 
Microfluidic devices operate with small volumes, offer exquisite control over the fluid flow8, 9, and make 56 
efficient use of materials, reagents and energy10. These advantages have been applied for the reproducible 57 
 2
formation of liposomes with uniform size distribution1, 6, 11. Typically, liposome formation occurs at the 58 
interface of an aqueous and a solvent phase, containing lipid molecules12, and microfluidic devices are well 59 
suited to establish and finely control such interfaces. In hydrodynamic flow focusing (HFF) devices, for 60 
example, where the solvent phase is microinjected in between two co-flows of aqueous buffer, liposomes 61 
with well-controlled size distributions can be assembled  6, 13. Furthermore, by changing the ratio between the 62 
flow rates of the aqueous buffer and organic phase, the concentration of lipid molecules in the organic 63 
phase, or by adapting the channel geometry, the size of the liposome can be finely prescribed 14, 15. Scaling 64 
up of HFF devices, however, is difficult which constrains the amount of liposomes that can be produced per 65 
unit time16. In contrast, devices based on chaotic advection micromixing11, 17 are more suitable for high 66 
throughput production of liposomes. Lipid nanoparticles with sizes between 20 and 50 nm were reported 67 
using a staggered herringbone mixer (SMH) by varying triglyceride ratios5. More recently, Kastner et al. used 68 
the same SMH to prepare liposomes encapsulating propofol18, a poorly water-soluble drug. These works 69 
demonstrate the potential application of microfluidics for the rapid, reproducible and size-controlled formation 70 
of drug-loaded liposomes.  71 
 72 
Purification remains a significant hurdle in the development of liposomal products. Irrespective of which 73 
production method is adopted, non-entrapped contaminant molecules, small molecule drugs or proteins must 74 
be removed from the final liposome product. Separation is typically achieved by filtration19, 20 or ultra-75 
centrifugation, which can be challenging for the large-scale purification. Other possible routes for removal of 76 
non-encapsulated material include dialysis, gel-permeation chromatography, ion-exchange chromatography, 77 
and size exclusion chromatography. However, these processes are time-intensive and can furthermore 78 
diminish product yield by column equilibration, which dilutes the final liposomal product, even with size 79 
exclusion chromatography21. 80 
 81 
To address these issues of post assembly refinement, here we investigate a lab-on-chip module-based 82 
microfluidic manufacturing and purification system for the production of liposomes. In contrast to previously 83 
reported on-chip devices by other groups and by us5, 18, 22, 23, where lengthy dialysis procedures for removal 84 
of non-entrapped drug and solvent residues were required, we present a novel continuous microfluidic 85 
liposome production and purification process train which generates purified liposomal products in less than 4 86 
minutes. Furthermore, the purification step is based on a tangential flow-filtration device with an easily 87 
exchangeable membrane, allowing therefore the purification of a broad variety of liposome formulations. This 88 
robust process train facilitates the identification of prospective formulations, optimal operating conditions and 89 
scale-up parameters, whilst significantly reducing the time required for developing versatile adjuvant and 90 
drug delivering systems. 91 
 92 
 93 
Results 94 
 95 
In order to obtain a continuous microfluidic liposome production and purification process train, we first 96 
characterised a tangential flow filtration (TFF) device24 and its purification capabilities for a variety of 97 
liposome formulations using lipids as outlined in Table 1. 98 
 99 
On-chip purification of liposomes for determination of the range of operational transmembrane 100 
pressures 101 
 102 
To identify the operational backpressure which yields the maximal recovery, we introduced in to the TFF 103 
device a commonly used formulation of neutral liposomes (PC:Chol; 1:1 molar ratio; Table 1). By varying the 104 
flow rates, and by implementing capillaries with different inner diameters and lengths downstream of the TFF 105 
device, we investigated backpressures from 7 to 80 psi (Table 2). To assess the liposome retention on the 106 
retentate side of the membrane (the volume of the liquid, which does not pass through the membrane), we 107 
collected samples from both the retentate and permeate (the volume which passes through the membrane), 108 
and measured the liposomal size and polydispersity index (PDI) at each of the backpressure conditions. The 109 
results (Fig. 1) show that there was no significant change in the size (approximately 115 nm) and PDI (0.15) 110 
of the liposome suspension in the retentate across the pressure range tested. However, at backpressures of 111 
75 psi and 80 psi, particles were detected in the permeate as confirmed by qualitative image-based 112 
nanoparticle tracking analysis NTA (Fig. 1). To confirm membrane integrity and exclude membrane damage 113 
as a possible cause for the liposome transferred into permeate, a leak-test applying pressures higher than 80 114 
psi was run and confirmed the membrane was intact. This suggests that at pressures above 75 psi, the TFF 115 
device was unable to retain liposomes and these were being pushed across the membrane into the retentate 116 
 117 
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The effect of filtration on particle characteristics of cationic and anionic liposomes 118 
 119 
After proving that neutral PC:Chol liposomes were retained, the application of the TFF to purify cationic 120 
(DDA:TDB; 8:1 molar ratio; Table 1) and anionic liposomes (DPPC:Chol:DPPG; 4:4:1 molar ratio; Table 1) 121 
was assessed (Fig. 2). The TFF device was first challenged with a batch-formulated cationic liposomal 122 
adjuvant (DDA:TDB) in three diafiltration cycles with buffer replenishment after each cycle, compensating for 123 
the volume of liquid passing into permeate. At a flow rate of 1 mL min-1, the backpressure was 49 psi 124 
(capillary length 50 mm, and I.D. 100 µm, Table 2), yielding a calculated flow rate of water through the 125 
cellulose membrane, Qtransmemb, of 0.25 mL·min
-1 (based on a linear extrapolation from supplier data; 16 mL 126 
min-1 cm-2 for 14.5 psi). 127 
 128 
With the cationic liposomes, the particle concentration of liposomes was 4.1 x 109 P/mL, which reduced to 129 
3.8 x 109 P/mL at the end of the third cycle (Fig. 2A) confirming the yield from the filtration process was 93% 130 
for the cationic liposomes. With these systems the liposomal size (approximately 300 nm) and cationic 131 
nature (approximately 60 mV) were not notably influenced by the filtration process (Fig. 2A). Furthermore, 132 
NTA analysis (Fig. 2B) showed that there were no cationic liposomes detected in the permeate.  133 
 134 
Similar results were demonstrated with anionic liposomes; filtration of batch-formulated anionic liposomes 135 
(DPPC:Chol:DPPG) using three diafiltration cycles produced no notable changes in terms of vesicle size 136 
(approximately 120 nm), PDI (0.14 to 0.15), ZP (-55 mV) and particle concentration (4.4 to 4.6 x 1010 P/mL) 137 
(Fig. 2). As with the neutral and cationic liposomes, NTA analysis in each diafiltration cycle verified that no 138 
liposomes were present in the permeate (Fig. 2B). 139 
 140 
Purification of non-incorporated drugs from liposome formulations 141 
 142 
Having successfully demonstrated the capability of the TFF to retain a wide range of different liposome 143 
systems, we then focused on investigating the efficiency of the TFF to purify the liposomal nanomedicines 144 
and remove non-incorporated drug (RC membrane, 10 kDa cutoff). To study drug removal, propofol (1 145 
mg.mL-1) was added to a suspension of negatively charged liposomes (DPPC:Chol:DPPG) in aqueous 146 
solution containing 20% (v/v) ethanol residual solvent levels found after liposome production by microfluidics 147 
prior to purification. Propofol, was employed as it has previously been studied as a low-solubility drug 148 
solubilised within liposomes. The TFF was shown to effectively purify the liposomes by removing both the 149 
solvent and non-incorporated drug with 90 % of the non-incorporated propofol being removed in the first 150 
diafiltration cycle, with a further removal of 80% in the second diafiltration run, and a further 60% after the 151 
third diafiltration cycle (Fig. 2C). Thus, after three cycles only 1% of the free non-incorporated drug 152 
remained within the formulation (Fig. 2C). Simultaneously, the TFF system removed the ethanol which had 153 
been used for the liposome formulation (Fig. 2C). Ethanol was reduced by approximately 50% in the first 154 
diafiltration cycle, and after three diafiltration cycles the residual ethanol concentration was 3% (v/v) (Fig. 155 
2C).  156 
 157 
Purification of ‘free’ protein from liposome formulations 158 
 159 
To investigate the removal of non-entrapped protein from liposome formulations, both cationic (DDA:TDB) 160 
and anionic liposomes (DPPC:Chol:DPPG) were considered given that electrostatic interactions between 161 
cationic liposomes and anionic proteins is exploited in the loading of antigens to liposomal adjuvant systems. 162 
Therefore both liposome systems were mixed with ovalbumin (OVA; 100 ȝg mL-1). At a flow rate for the 163 
retentate of 2.5 mL min-1, the backpressure was 62 psi (capillary length 25 mm, and I.D. 100 µm, Table 2), 164 
yielding a calculated flow rate of water through the PES membrane (MWCO 300 kDa), Qtransmemb, of 1.69 165 
mL·min-1 (based on a linear extrapolation from supplier data; 58 mL min-1 cm-2 for 10 psi). Thus, from 2.5 mL 166 
initial sample only 0.81 mL remain in the retentate fraction, and 1.69 mL pass through the membrane. The 167 
theoretical volume of permeate accounted for 67% of the initial liquid. 168 
 169 
Given the anionic nature of OVA at the pH range used, electrostatic interactions with the cationic but not the 170 
anionic liposomes occurred. Indeed, anionic liposomes maintained a similar size (approximately 120 nm) 171 
after the addition of OVA (Fig. 3A); however, for the cationic liposomes, the electrostatic interactions with the 172 
anionic OVA resulted in aggregation and in an increased vesicle size from around 220 nm to 300 nm, and a 173 
drop in their cationic nature from 59.8 ± 1.9 mV to 17.5 ± 1.4 mV (Fig. 3B).  174 
 175 
After the addition of protein, both systems were subjected to three diafiltration cycles. The size and PDI of 176 
both the anionic (Fig. 3A) and cationic (Fig. 3B) liposomes were not significantly altered through the course 177 
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of the diafiltration cycles and particle recovery was 87% and 96%, respectively (Fig. 3). Protein (OVA) and 178 
residual ethanol was removed into the permeate stream over the three diafiltration cycles, with a final 179 
removal of 70% of the free protein and 95% of the solvent with the anionic liposomes (Fig. 3C). Similar 180 
results were achieved with the cationic liposome systems (Fig. 3D); by using TFF purification, ethanol 181 
residues were reduced to 4% (v/v) of the starting value and 75% protein was removed (Fig. 3B) after three 182 
diafiltration cycles. The reduced levels of protein removed from the cationic system were a result of protein 183 
loading onto the surface of the liposomes due to electrostatic interactions (but not related to the filtration 184 
process in the TFF). 185 
 186 
Micro continuous-flow system for production, modification and purification of liposomes 187 
 188 
Having established the efficacy of the TFF purification system, the next stage was to develop a continuous 189 
manufacturing and purification process for liposomes. To achieve this, a staggered herringbone micromixer 190 
(SHM) was employed to generate the liposomal systems and directly feed the TFF device with the 191 
liposomes. To optimise the throughput for each of the two devices separately, and to independently control 192 
the flow rates, an intermediate collection vial was used (Fig. 4). Furthermore, the intermediate collection vial 193 
allowed purification of the liposomes in diafiltration mode. After each diafiltration cycle, fresh buffer was 194 
added manually into the intermediate vial to compensate for the volume passing through the membrane into 195 
the permeate. Continuous production (Fig. 4) was demonstrated by using 1) neutral liposomes (PC:Chol, 4:1 196 
molar ratio) with propofol and 2) cationic liposomes (DOPE:DOTAP, 1:1 molar ratio; Table 1) loaded with 197 
surface-complexed protein. Lipid recovery after 4 diafiltration cycles remained at 100%, matching the initial 198 
amount of lipids present prior to TFF (Fig. 5A). Without buffer replenishment, the system performed 199 
concentration cycles for formulations (Fig. 5B). Within four cycles, the concentration of lipids measured in the 200 
retentate doubled (Fig. 5B). This was due to a 50% reduction in volume as the overall quantity of lipids in the 201 
retentate remained constant, matching the lipid content after the SHM (but before the TFF). 202 
 203 
Continuous manufacture and purification of liposomes with bilayer loaded drug 204 
 205 
This system was then applied for the continuous manufacture and purification of liposomes incorporating 206 
propofol (Fig. 4B). Liposome (PC:Chol) production and drug encapsulation were performed in a staggered 207 
herringbone mixer (SHM), operated with a volumetric flow rate of 2 mL min-1 and a 1:3 solvent:aqueous 208 
buffer ratio. The resulting liposomes were 50 nm in size with a PDI of 0.3 (Table 3) in line with previously 209 
reported studies25. Using the continuous manufacturing set up (with three diafilitrations), liposomes were 210 
therefore both manufactured and purified. This continuous system was able to produce a purified liposome 211 
product incorporating 51 mol% propofol (in line with previously reported drug loading achieved using a 2 step 212 
manufacture and purification process based on dialysis18), with clinically acceptable ethanol levels (3% (v/v); 213 
Table 3). Furthermore, liposomes manufactured and purified in this continuous systems retained their 214 
physico-chemical attributes and were not significantly different in size, nor PDI from those not subjected to 215 
TFF purification (Table 3). Examples of electron microscopy images of liposomes are shown in 216 
Supplementary Figures S1 and S2. 217 
 218 
To compare the characteristics and drug loading of PC:Chol liposomes loaded with propofol, the same 219 
formulation was prepared using hand-held extrusion (10 passes through a 400 nm, 200 nm, 100 nm and final 220 
50 nm pore size filters). Whilst this method of liposome manufacture was not the main focus of this study and 221 
could be further optimized, again these liposomes were effectively purified to remove free drug using TFF 222 
(with drug loading of 3.6 ± 0.38 mol %; data not shown) and the liposome size and PDI remained unchanged 223 
by TFF purification (107.9 ± 14.1 nm and 109.9 ± 19.0 nm with PDI values of 0.17 ± 0.10 and 0.34 ± 0.06 pre 224 
and post TFF purification respectively, results not shown).  225 
 226 
Continuous manufacture and purification of cationic liposomes with adsorbed protein 227 
 228 
The lab-on-chip micro continuous-flow system was next challenged with the production of cationic 229 
(DOPE:DOTAP) liposomes, which were modified with added ovalbumin in the intermediate connection vial 230 
and finally subjected to purification (Fig. 4C). Lipids were included in the ethanol stream and liposome 231 
formation was performed using the SHM, which operated at 2 mL min-1 and a 1:3 solvent:aqueous buffer 232 
ratio. The outflowing liposome solvent mixture was collected in the intermediate collection vial after 1 minute 233 
of SHM operation, and analysed (size, PDI, ZP). The resulting liposomes had a size of 62.8 ± 1.9 nm, PDI of 234 
0.4 ± 0.02 and ZP of 84 ± 3.5 mV prior to addition of OVA. Then ovalbumin was added to the intermediate 235 
vial, resulting in vesicles with a larger size (88.5 ± 5.7 nm), unaltered polydispersity (0.45 ± 0.01), and 236 
reduced ZP (43.6 ± 1.6 mV) (Table 4), again as a result of interactions between the cationic liposomes and 237 
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the anionic protein. After manufacture and purification on the system, liposomes were unaltered in size (89.3 238 
± 10.9 nm; PDI 0.42 ± 0.02) and had an increased ZP (69.2 ± 6.1 mV) (Table 4), presumably through the 239 
purification and removal of 74% free protein from the system. Residual solvent levels were also reduced to 240 
clinically acceptable levels (4 %; Table 4). Examples of electron microscopy images of liposomes are shown 241 
in Supplementary Figure S1. 242 
  243 
Discussion 244 
 245 
We successfully investigated the region of operation for the Tangential Flow Filtration (TFF) device with 246 
various liposome formulations and confirmed the upper limit of operational pressure for the presented 247 
purification system to be 75 psi. A pressure range between 5 and 80 psi is a common backpressure 248 
implemented in industrial filtrations26 which is virtually identical to our TFF. During pressure tests, the 249 
membrane remained intact throughout, and therefore it can be considered that the measured backpressure 250 
equaled the transmembrane pressure inside the TFF. This transmembrane pressure could be adjusted 251 
accordingly using the data available in Table 2; alternatively, it could be calculated from Hagen Poiseuilles 252 
equation. Based on these findings we determined the optimal operational transmembrane pressure of 62 psi, 253 
which corresponded to a maximum flow rate of 2.5 mL min-1 through a restrictive capillary with an internal 254 
diameter of 100 µm and a length of 25 mm. At this flow rate, our sample (2 mL) took less than a minute (~48 255 
s) to run through the system, which shows a distinct advantage over the current methods that require lengthy 256 
bench-top, post-synthetic dialysis22. At high shear rates, drug release from liposomes can be a problem. 257 
However, the calculated average shear rate at the maximum flow rate of 2.5 mL min-1 inside the retentate 258 
channel is approximately 590 s-1 (Supplementary Information S3). This value is lower than previously 259 
reported shear rates27 of 800 s-1 for which no influence on the permeability or integrity of the liposome 260 
membranes was found. Furthermore, the flow rates matched those previously applied for liposome 261 
manufacturing using a device with a SHM5, 25. Thus, we proved that a SHM can be coupled directly with the 262 
TFF, and that we could generate and purify liposomes in a continuous mode without any losses into the 263 
permeate. Overall our results show that our filtration system can be implemented for multistage purification of 264 
a broad range of liposomal products. 265 
  266 
Backpressures of 75 psi and higher, however, led to losses of liposomes through the intact cellulose 267 
membrane into the permeate. One possible explanation could be that of particle extrusion across the 268 
membrane at these high pressures. It is well known that liposomes can undergo extrusion through cylindrical 269 
pores in membranes. Industrial scale extrusion tends to use higher lipid concentration than in our current 270 
study and adopts higher pressures ranging between 100-700 psi. However, extrusion of liposomes is system 271 
dependent; polycarbonate filters are used at pressures less than 100 psi, and low lipid concentrations 272 
require lower pressure28. Therefore, to avoid extrusion, a backpressure of 75 psi was adopted as the critical 273 
cut off value. Membrane characteristics also play an important role for liposome recovery as they influence 274 
the flux from the retentate to the permeate. The calculated transmembrane flow was 0.32 mL min-1 (or 12.8% 275 
of the total flow rate, TFR) for a hydrophilic membrane with a pore size of 0.22 µm, at a backpressure of 62 276 
psi and nominal flow rate of 2.50 mL min-1 (retentate). In contrast, for the same backpressure and same 277 
nominal flow rate, a membrane with a 0.45 µm pore size resulted in a transmembrane flux of 1.69 mL min-1, 278 
corresponding to 67.6% of the retentate inflow. Furthermore, the presented setup demonstrates that a range 279 
of capillaries with varying inner diameter and length can be applied to control the backpressure and the 280 
dilution or concentration rates of the system, allowing to tailor resulting flow rates and to adjust throughputs. 281 
 282 
Having established optimal operational conditions of our TFF device, its purification capacity for the removal 283 
of non-incorporated hydrophobic drug (propofol) and residual ethanol was studied. Over three diafiltration 284 
cycles, the quantity and quality of liposomes were preserved after purification for the anionic vesicles. For the 285 
cationic liposomes, there was a small increase in polydispersity, but no significant increase in liposome size 286 
(Fig. 2A). The propofol content decreases much faster in comparison to the ethanol (Fig. 2B), with the 287 
hydrophilic membrane (0.22 µm pore size). This could potentially be due to capillary action that channels the 288 
separation of lipophilic propofol29 (Log Kow=3.79) through the membrane. The ethanol content was the critical 289 
factor, which determined the required number of diafiltration cycles. After three diafiltration cycles, only 1% of 290 
non-incorporated propofol and 3% residual ethanol remained within the liposomal suspension with no 291 
changes in liposome physico-chemical attributes or concentration (Fig. 2) demonstrating the ability of this 292 
system to provide liposomes purified to a level as would be expected for a therapeutic product.  293 
 294 
In terms of removal of non-associated protein from liposomes, as might be required for liposomal adjuvants 295 
or biological therapeutics, protein removal is challenging because high concentrations of protein can lead to 296 
membrane fouling due to protein-membrane interactions24. Such protein-membrane interactions occur due to 297 
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electrostatic repulsion forces. Similar to propofol removal, the dilution by replenishing with fresh buffer, and 298 
subsequent filtration facilitates the reduction in concentration of free protein in the retentate. Purification 299 
therefore occurs as a result of two cumulative effects: one from the separation at the membrane and the 300 
other from the dilution of the retentate. As demonstrated, separation can be controlled by adjusting flow rates 301 
and restrictive capillary sizes; also by varying the amount of liquid that is replenished after each diafiltration 302 
cycle. In our results, the volume amounted to the volume of the permeate, thus maintaining constant the 303 
amount of liquid circulating in lab-on-chip purification system.  304 
 305 
The tolerated levels of free protein depend on the requirements implied by the target application of the 306 
liposomes and the number of diafiltration cycles can be adjusted accordingly to match those criteria for 307 
purity. A particular focus in the delivery of protein antigens is the use of cationic liposomes, with electrostatic 308 
attractive forces dominating and often leading to a surface-adsorption reaching close to 100% depending on 309 
protein concentrations used30 and purification can further be complicated by the cross-linking and/or 310 
aggregation of cationic liposomes (DDA:TDB) with protein. We have demonstrated the capability of the 311 
filtration device to separate non-adsorbed ovalbumin (OVA) from a cationic liposome formulation and 312 
residual solvent with high liposome adjuvants recovery (87%) (Fig. 3). This presents compelling evidence 313 
that our micro continuous-flow purification device, i.e. TFF device, is capable of providing an effective post-314 
production purification step, with the option to recycle purified protein for subsequent applications. 315 
 316 
The liposome process flow system presented here (Fig. 4) facilitates the complete removal of the free drug, 317 
which was previously only achievable by time intensive, bench-top dialysis18, 22. The encapsulation and 318 
solubilisation of drug with low aqueous solubility in the bilayer of liposomes has been investigated previously 319 
using a microfluidics based system18. In that study the assembly of PC:Chol liposomes was performed using 320 
a SHM, and the method was established as a robust, reproducible approach for preparing size-controlled 321 
liposomes as solubilising agents. The same SHM is implemented in this herein reported system to 322 
investigate the effects of continuous processing on drug encapsulation by measuring amounts of drug 323 
encapsulated in the liposome bilayer. Very importantly, the amount of encapsulated drug and physical 324 
characteristics (size, PDI) show that continuous processing and the pressures applied in the TFF have no 325 
adverse effect on liposome integrity (Table 3). The presented assembly utilizes the methanol solubilisation 326 
as the initial step of liposome production. However, it is possible to replace time-intensive production and 327 
dialysis (hours) with a micro continuous-flow system (minute-long process) manufacturing and purification to 328 
rapidly remove residual solvent. Among the main merits of using the continuous microfluidic process flow are 329 
the mild conditions during the assembly of the liposomes and the replacement of long ultracentrifugation 330 
steps for protein removal31. It can be concluded that the performance of the process flow system 331 
demonstrated (Fig. 4) for liposomes is consistent with: (i) the results from the stand-alone SHM in terms of 332 
particle characteristic; (ii) the results from the stand alone TFF in terms of purification. 333 
 334 
Conclusions 335 
 336 
We have successfully demonstrated for the first time the feasibility for on-chip purification of liposomal 337 
batches for process development. Liposome manufacture, drug loading and removal of contaminants (such 338 
as un-entrapped drug or protein as well as solvent residues) were performed in a continuous mode using two 339 
microfluidic devices, allowing for manufacturing, purification and concentration of liposomal drug products. 340 
These devices were successfully challenged with a range of liposomes, varying in lipid composition, surface 341 
potential, size and concentration. The results demonstrate the ability of the on-chip filtration unit to be 342 
tailored to a broad diversity of lipid-based nanoparticles by varying the operational parameters. The 343 
microfluidic devices allow for an efficient and quick investigation of several lipid or drug candidates, and meet 344 
high throughput requirements of early stage development processes. The continuous process may permit 345 
determination of liposomal characteristics (e.g. size, surface potential, particle number) and encapsulation 346 
efficiencies of a wide variety of drug molecules, allowing for future integration of process analytical 347 
technologies (PAT) to further aid reproducibility. Furthermore, the setup is of considerable interest for cost-348 
intensive drugs or protein encapsulation development, as the process requires micro volumes. The 349 
microfluidic device developed herein can cope with a variety of proteins developed by the biopharmaceutical 350 
industry. The device has the flexibility of integrating different types of membranes to cater for a variety of 351 
uses; also has the option of scalability through parallelization of the mixer chips and TFF membranes, and 352 
thereby can be easily translated to industrial setting32.  353 
 354 
Methods 355 
 356 
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Chemicals 357 
 358 
Egg Phosphatidylcholine (PC), CAS: 8002-43-5, 1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) 359 
sodium salt (DPPG), CAS: 67232-81-9, 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), CAS: 63-89-8 360 
and Cholesterol (Chol), CAS: 57-88-5 were obtained from Sigma-Aldrich Company Ltd. (Poole, UK). 1,2-361 
dioleoyl-sn-glycero-3-phsphoethanolamine (DOPE), CAS: 4004-05-1, 1,2-dioleoyl-3-trimethylammonium-362 
propane (DOTAP), CAS: 144189-73-1, dimethyldioctadecylammonium bromide (DDA), CAS: 3700-67-2 and 363 
trehalose 6,6-dibehenate (TDB), CAS: 66758-35-8 were purchased from Avanti Polar Lipids, Inc., (Alabaster, 364 
AL), purity >99% (Table I). Ethanol, CAS: 64-17-5, and methanol, CAS: 67-56-1, were obtained from Fisher 365 
Scientific (Loughborough, UK). TRIS Ultra Pure, CAS: 77-86-1, was obtained from ICN Biomedicals, Inc., 366 
(Aurora, Ohio). Propofol (2,6-Bis(isopropyl)phenol), CAS: 2078-54-8 and ovalbumin (chicken egg), CAS: 367 
9006-59-1 were obtained from Sigma-Aldrich Company Ltd., (Poole, UK). Ultrafiltration regenerated cellulose 368 
membranes (p\n: U2755-10AE) were obtained from Sigma-Aldrich Company Ltd., (Poole, UK) (10kDa, pore 369 
size 0.22 µm), and Biomax polyethersulfone ultrafiltration membrane discs with 300 kDa cutoff, pore size 370 
0.45 µm (p\n: PBMK06210) from Merck Milipore (Darmstadt, Germany).  371 
 372 
Liposome batch formulations for characterisation of the Tangential-Flow Filtration (TFF) device  373 
 374 
Multilamellar vesicles (MLV) were prepared using the lipid film hydration method33. Lipids were weighed and 375 
dissolved in a chloroform/methanol (9:1 v/v) mixture. Cationic liposomes comprised DDA:TDB (8:1 molar 376 
ratio) and anionic liposomes comprised DPPG, DPPC, Chol (1:1:1.3 molar ratio). The organic solvent was 377 
subsequently removed by rotary evaporation under vacuum (100 RPM, 180 mBar, Rotavapor R-100, BÜCHI 378 
Labortechnik AG, Switzerland), followed by flushing with nitrogen for removal of solvent residues (5 minutes). 379 
The thin lipid film on the bottom of a round bottom flask was hydrated with 10 mM pH 7.2 TRIS buffer. Small 380 
liposomes were formed via probe sonication (Soniprep150plus, MSE, UK; 5 min at amplitude of 5). Ethanol 381 
was manually added to the liposome formulation to a final concentration of 20% (v/v) to simulate solvent 382 
contents commonly resulting from the microfluidics production method. Ovalbumin (100 ȝg mL-1) was used 383 
as a model protein, and propofol (1 mg mL-1) as a model drug. These were added to the liposome 384 
formulation post-production to mimic the conditions post liposome manufacturing by microfluidics. 385 
 386 
Device fabrication 387 
 388 
As previously reported, the filtration system was designed to seal membranes in place by means of 389 
mechanical clamping24. Two poly(methylmethacrylate) (PMMA) plates, with a straight channel (1 mm width, 1 390 
mm depth, 45 mm length) and a 1 mm hole milled at each end were clamped together using M3 screws 391 
along the edges (Torque 10 Ncm). A 1 mm wide and 0.75 mm deep cutting was used to hold the PDMS 392 
gasket in place, which was used to secure the membrane in place (Supplementary Figure S4). Different 393 
commercially available membrane sheets were cut to the required size using a CO2 laser marking head 394 
(Synrad Inc., Mukilteo, WA, USA). The membranes used in this set of experiments had a cut-off of 10kDa or 395 
300kDa, for drug or protein filtration, respectively. The membranes were cleaned after each experiment by 396 
back-flushing with water and stored inside the TFF system in 0.8 M saline solution, ready for the next 397 
experiment. 398 
 399 
Additionally, a clamping system was made from PMMA (two plates held together by screws [M3]) for the 400 
staggered herringbone micromixer (SHM) chip using a micromilling machine (M3400E, Folken IND, 401 
Glendale, USA). The gasket for the filtration unit was manufactured from poly(dimethylsiloxane) (PDMS, 402 
Sylgard 184, Dow Corning, Midland, USA), according to the manufacturers instructions and cast in PMMA 403 
moulds, manufactured as described above. Interconnect ports (milled from 5 mm PMMA), with two holes 404 
tapped with an M3 thread were used for connection to the filtration unit; an M6 threaded hole was used for 405 
standard connection fittings (P-221, Upchurch Scientific, Oak Harbor, WA, USA).  406 
 407 
Backpressure regulation  408 
 409 
Backpressures were regulated through capillaries, which were attached to the retentate outlet of the filtration 410 
device (see Supplementary Fig. S3 online). These capillaries restricted the flow as they were selected with 411 
internal diameters smaller than the polytetrafluoroethylene (PTFE) tubing (1/16 in. x 0.031 in., p\n: 58700-U, 412 
Sigma- Aldrich Int.) which connected the TFF device with auxiliary pumps and collection vials. Backpressure 413 
was calculated using Hagen-Poiseuilles Law 414  ?ܲ ൌ ଵଶ଼ 긌? ?௅ ?ொగ ?஽ర       (1) 415 
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 416 
where µ, L, d and Q are the dynamic viscosity of the medium at 25 oC, the length and internal diameter of the 417 
restricting capillary, and the volumetric flow rate, respectively. We used Hagen-Poiseuilles equation (1) to 418 
select the capillary sizes and the flow rates to attain the backpressure range from 5 to 80 psi. For each 419 
backpressure analysis, a capillary was connected to the TFF retentate outlet using PTFE tubing, ferrules 420 
(p\n: P-200, IDEX Europe GmbH, Germany) connectors (Flangeless Nuts, p\n: P-247, PEEK, M6 Flat-421 
Bottom, for 1/16 in. OD, IDEX Europe GmbH, Germany) and metric unions (Metric Union, M6 Port, p\n: P-422 
602, IDEX Europe GmbH, Germany). The inlet of the TFF was connected through a Luer-lock fitting and 423 
polytetrafluoroethylene PTFE tubing to a single-use plastic syringe. Water was fed in the TFF device at 424 
discrete flow rates ranging from 0.01 to 2.5 mL min-1 attained by a syringe pump (Nemesys, Cetoni GmbH, 425 
Germany). Backpressures were measured experimentally with a pressure sensor (40PC100, Honeywell, NJ, 426 
USA) connected on the retentate side; the data was logged with a LabVIEW virtual instrument (National 427 
Instruments, TX, USA). We compared the theoretical backpressures from equation (1) to the measured 428 
backpressures, and the measured values exceeded their calculated counterparts from 20% to 6.25% when 429 
increasing the applied backpressure from 5 to 80 psi, respectively (Supplementary Figure S5, and 430 
Supplementary Table S6). One of the TFF outlets was intentionally sealed with a flat bottom plug (p\n: P-431 
314, M6, IDEX Europe GmbH, Germany) while a single outlet connected through a ferrule (p\n: P-200), nut 432 
(p\n: P-247) and tubing into a collection vial for liquid passing through the membrane. 433 
 434 
Filtration  435 
  436 
Filtration was performed in diafiltration mode to investigate the liposome behaviour in the established 437 
pressure and flow rate range (Table 2). For this experiment, bench-top prepared liposomes in aqueous 438 
solution were spiked with drug, protein or solvent, and were introduced into the TFF by means of syringe 439 
pumps (Nemesys, Cetoni GmbH, Germany), connectors and capillaries as described earlier. A capillary was 440 
connected to the TFF, in cis-configuration (on the same side of the membrane), and closed the loop of the 441 
retentate fluidic line (see Supplementary Fig. S3 online). Retentate from the TFF was collected in an 442 
intermediate collection vial and could be injected in the device hence allowing for multiple passes, referred in 443 
this article as diafiltration cycles. Transmembrane pressure was attained by controlling the flow rates in the 444 
pump; also by adding a constriction capillary of known geometry, i.e. internal diameter and length. Retentate 445 
and permeate fractions were collected in Eppendorf tubes, assessed by weight, and used for further 446 
analysis, i.e. zeta potential, size, polydispersity, quantification via HPLC. A volume of TRIS buffer, 10 mM pH 447 
7.2, was added after each diafiltration cycle to compensate for the amount of liquid passing through the 448 
membrane (in permeate) and to sustain steady concentration levels (in retentate) during the continuous 449 
purification process. 450 
 451 
Continuous process flow configuration 452 
 453 
To test the continuous processing of liposome formation followed by liposome purification, a SHM and a TFF 454 
device were connected in sequence. The SHM (Precision Nanosystems Inc., Vancouver, Canada) consisted 455 
of two inlets, a bifurcated channel with herringbone structures, and single outlet moulded in PDMS. The 456 
channels were 200 ȝm in width and 79 ȝm in height with herringbone features of 50 ȝm in width, 31 ȝm in 457 
height, 45° angle, asymmetry index 2:1 (according to Precision Nanosystems, Inc.). Luer-lock fitting and 458 
polytetrafluoroethylene (PTFE) tubing (1/16 in. x 0.031 in., Sigma- Aldrich Int.) were used to link disposable 1 459 
mL syringes with the two inlet ports of the chip; flow rates and flow rate ratios were controlled by syringe 460 
pumps (Nemesys, Cetoni GmbH, Germany) and the whole system was primed with Tris buffer (10 mM, pH 461 
7.2) prior to operation. Organic phase, a weighed amount of lipids in ethanol, was injected into the first inlet 462 
of the SHM device, while in the second inlet aqueous phase (TRIS buffer, 10mM, pH 7.2) was injected. The 463 
micromixer was held in place using a clamping device made out of PMMA. The micromixer was connected to 464 
the tangential flow filtration unit via an intermediate collection vial (2.0 mL Eppendorf) for additional 465 
functionality. This allows the addition of various components such as of microfluidics-manufactured 466 
liposomes prior to the filtration system for purification. A bi-directional milliGAT pump (VICI Valco, Valco 467 
Instruments Co.) was connected in-line with the retentate loop of the TFF through a capillary at the bottom of 468 
that intermediate collection vial. Transmembrane pressures was varied by restricting the flow of the retentate 469 
using different small diameter capillaries connected in-line with the TFF outlet. The retentate flowed through 470 
the capillary and was collected in the intermediate vial, while permeate passed through the membrane and 471 
was gathered in a separate tube. Both fractions were analysed for content of liposomes, propofol, protein, 472 
lipid and ethanol. 473 
  474 
Two different liposome formulations were produced using the coupled SHM to TFF systems. For the 475 
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preparation of neutral liposomes, PC and Chol (4:1 molar ratio) in ethanol were injected into the micromixer 476 
at a total flow rate (TFR) of 2 mL min-1 and a flow rate ratio (FRR) of 1:3; bilayer drug loading was achieved 477 
by including 1 mg mL-1 of propofol in the solvent stream. For the preparation of a cationic liposome 478 
formulation, DOPE and DOTAP (1:1 molar ratio) in ethanol were injected into the micromixer at a TFR of 2 479 
mL min-1 at FRR 1:3. After formulation, the required amount of protein (ovalbumin, 100 ȝg mL-1) was added 480 
to the intermediate collection vial. Manually adding fresh solution to the intermediate collection vial 481 
compensated for liquid passing through the membrane into permeate. Otherwise, the amount of the fluid in 482 
the system would fall below a critical level and purification would need to be interrupted because of 483 
insufficient circulating liquid volume. 484 
 485 
Measurement of particle characteristics 486 
 487 
Nanoparticle tracking analysis (NTA) was performed with a Nanosight LM20 (NanoSight, Amesbury, UK), 488 
connected to a microscope (with 20× magnification). Liposomes were diluted 1:10 to 1:100 in distilled water, 489 
to achieve an optimal particle concentration of 107  109 particles/mL during measurement. NTA analysis 490 
was used to determine the particle concentration per millilitre (P/mL), recording time was 60 seconds and 491 
camera settings (shutter and gain) were adjusted manually to maximise resolution. Dynamic light scattering 492 
(DLS) (Malvern Zetasizer Nano-ZS, Malvern Instruments, Worcestershire, UK) was used to report the z-493 
average (intensity based mean particle diameter), and to report the polydispersity (PDI), in order to assess 494 
the width of the particle distribution. Liposomes were diluted 1:10 in distilled water and measurements took 495 
place at 25°C.  Zeta potential (ZP) was measured using particle electrophoresis (Malvern NanoZS, Malvern 496 
Instruments, Worcestershire, UK).  497 
 498 
Propofol quantification 499 
 500 
Quantification of propofol was performed by reverse phase HPLC (Luna 5µ C18, Phenomenex, UK, pore 501 
size of 100Å, particle size of 5 µm) at 268 nm. The flow rate was constant at 1 mL min-1 throughout with a 502 
gradient elution from 5:95 (Methanol: 0.1% Trifluoroacetic Acid, TFA, in water) to 100:0 (Methanol: 0.1% TFA 503 
in water) over 10 minutes. HPLC-grade solvents were used, sonicated and filtered. The column temperature 504 
was controlled at 35°C. All analysis was made with Clarity, DataApex, version 4.0 (DataApex, Prague, Czech 505 
Republic). For quantification, established calibration curves of propofol were used as reported previously14.  506 
 507 
Protein and lipid quantification 508 
 509 
Samples were loaded on a HPLC and elution was performed with a gradient from 5:95 to 100:0 (Methanol: 510 
0.1% TFA in water) over 20 and 40 minutes for protein and lipid detection, respectively. Quantification was 511 
performed by an evaporative light scattering detector (ELSD) (Sedex 90, Sedere, France), set at 52°C and 512 
coupled to the HPLC as described previously18. A calibration curve was established from standards 513 
(ovalbumin in TRIS buffer, pH 7.2, lipids in ethanol) in six replicates at concentrations from 5 to 100 ȝg mL-1 514 
(protein) and 0.05 to 1.5 mg mL-1 (lipids). 515 
 516 
Ethanol quantification 517 
 518 
Solvent concentration was quantified by gas chromatography (GC) using a flame ionization detector (CSi 519 
200 Series, column TRACE 15 m x 0.25 mm x 0.25 µm TR-5, Thermo Scientific, UK), with detector 520 
temperature 230°C, injector temperature 200°C and an injection volume of 1 µL. The carrier gas was helium 521 
at 15 psi inlet pressure. A calibration curve (6 standards ranging from 0.5-50% v/v) was established and 522 
used for quantification using an internal reference standard (propan-1-ol). All analysis was made in Clarity 523 
DataApex version 2.4 (see above). 524 
 525 
Statistical analysis 526 
 527 
Unless stated otherwise, results were reported as the mean ± one standard deviation (SD., n=3). One- or 528 
two-way analysis of variance (ANOVA) was used to assess statistical significance, followed by Tukeys 529 
multiple comparing test (post-hoc analysis). A t-test was performed for paired comparisons. Significance was 530 
acknowledged for p values lower than 0.05, marked with and asterisk (*). All calculations were made in 531 
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, US). 532 
 533 
 534 
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Figure 1: Particle size and polydispersity as a function of increasing backpressures in the TFF system as 690 
collected on the retentate side of the membrane. Images from NTA analysis, verifying particles in permeate 691 
(top) and retentate (bottom) stream at increasing backpressures. Particles were found in the permeate at 692 
backpressures exceeding 75 psi. All experimental datasets are presented as mean and standard deviation 693 
(mean ± s.d.) resulting from three independent runs (n=3). 694 
Figure 2: (a) Vesicle size, polydispersity (PDI), zeta potential (ZP) and particle concentration (P/mL) for 695 
cationic (DDA:TDB) and anionic (DPPG:DPPC:Chol) liposomes before and after the TFF purification. (a) 696 
Images from NTA show vesicles present in the retentate side only.(c) Propofol and ethanol removal achieved 697 
over three diafiltration cycles for anionic liposomes (DPPG:DPPC:Chol), expressed as a percentage of the 698 
initial amount of contaminants present. 699 
Figure 3: Vesicle size, polydispersity (PDI), zeta potential (ZP) and particle concentration (P/mL) for (a) 700 
anionic liposomes (DPPG:DPPC:Chol) and (b) cationic liposomes (DDA:TDB) prior and post OVA-addition 701 
(ovalbumin, 100 ȝg mL-1), and particle characteristics after the TFF purification. Protein (ovalbumin) and 702 
ethanol removal achieved over three diafiltration cycles for (c) anionic and (d) cationic liposomes, expressed 703 
as a percentage of the initial amount of contaminants present. All experimental datasets are presented as 704 
mean and standard deviation (mean ± s.d.) average of three independent runs (n=3). 705 
Figure 4: (a) Schematic overview of the module-based microfluidic system. Liposomes were manufactured 706 
with a Staggered Herringbone Mixer (SHM) upstream and flowed through the Tangential Flow Filtration 707 
(TFF) device for consecutive purification. (b) Schematic overview of the formation of liposomes loaded with a 708 
low-solubility model drug, i.e. propofol. Vesicle assembly and drug loading are performed with a SHM, and 709 
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non-entrapped (free) drug is removed from the mixture by consecutive filtration inside the TFF system. (c) 710 
Schematic overview of the formation of liposomes loaded with a model protein, ovalbumin (OVA). Vesicle 711 
assembly is performed with a SHM, with post-assembly protein addition; non-entrapped (free) protein is 712 
removed by consecutive diafiltration cycles inside the TFF system. 713 
Figure 5: Lipid recovery in the continuous liposome factory-on-a-bench for (a) lipid recovery after four 714 
diafiltration cycles. (b) Lipid concentration in four concentration cycles, related to the initial amount of lipids 715 
present prior to the concentration cycles. All experimental datasets are presented as mean and standard 716 
deviation (mean ± s.d.) average of three independent runs (n=3). 717 
 718 
Table 1: Lipids investigated in this study. 719 
Lipid Application Reference 
Dimethyldioctadecyl ammonium 
bromide 
(DDA) 
Vaccine adjuvant,cationic head group
 
Uptake of vaccine antigens to antigen 
presenting cells  
 
Smith Korsholm et al.
34
  
 
Christensen et al.
35
 
Trehalose 6,6-dibehenate  
(TDB) 
 
Synthetic immunstimmulator derived 
from the membrane of mycobacterium  
1,2-dioleoyl-sn-glycero-3-
phsphoethanolamine  
(DOPE) 
 
Fusogenic helper lipid, available in the 
commercial Lipofectin transfection 
reagent  
Henriksen-Lacey et al.
36
 
1,2-dioleoyl-3-
trimethylammonium-propane 
(DOTAP) 
 
Cationic lipid often used in transfection 
Egg Phosphatidylcholine  
(PC) 
Neutral head group, drug delivery Senior and Gregoriadis
37
 
Gregoriadis and Senior
38
  
1,2-Dipalmitoyl-sn-glycero-3-
phospho-rac-(1-glycerol)  
(DPPG) 
 
Negative charged head group 
drug delivery 
Oku et al.
39
 
 
Kirby et al.
40
  
 
1,2- Dipalmitoyl-sn-glycero-3-
phosphocholine  
(DPPC) 
 
Neutral head group, drug delivery
Cholesterol (Chol) Added for membrane stabilization, 
known to effect drug encapsulation 
efficiency in bilayer and aqueous core 
Senior and Gregoriadis
37
 
Kirby et al.
40
 
 720 
 721 
 722 
Table 2: Backpressures and flow rates through the Tangential Flow Filter (TFF) that were investigated in this study. 723 
Liposomes in solution were fed into the TFF device at flow rates ranging between 0.01 and 2.5 mL min
-1
. Backpressure 724 
was attained by connecting a restrictive capillary with selected (I.D.) and/or length on the retentate side of the TFF 725 
outlet. 726 
Backpressure (psi) 7 15 23 31 39 49 50 59 62 75 80
 14
Flow rate (mL min
-1
) 0.01 0.02 0.03 0.1 0.05 1 0.3 2 2.5 0.5 0.1
Capillary I.D. (ʅm) 50 50 50 63 50 100 63 100 100 63 50
Capillary length(mm) 50 50 50 50 50 50 25 30 25 25 50
 727 
 728 
 729 
Table 3: Continuous purification of PC:Chol liposomes loaded with propofol. Propofol and lipids were included in the 730 
ethanol stream. Liposome formation and drug encapsulation was performed in a staggered herringbone mixer (SHM), 731 
operated with a total flow rate of 2mL min
-1
 and a ratio of 1:3 ethanol:aqueous solution. The results are presented as 732 
mean and standard deviation (mean ± s.d.) resulting from three independent runs (n=3), N/A = not applicable. 733 
  Liposome with drug after SHM Liposome with drug after three passes 
through the TFF
* 
Size (nm) 51.4 ± 2.1 61.2 ± 13.2
Polydispersity 0.29 ± 0.013 0.33 ± 0.09
Loading (mol%) N/A 51.0 ± 4.0
Effec. ethanol (% v/v) 16.1 ± 3.9 3.1 ± 1.5
*
After each pass a volume of pure buffer was added to compensate for permate and maintain constant volume of retentate. 734 
 735 
 736 
Table 4: Continuous purification of DOPE:DOTAP liposomes loaded with protein (ovalbumin). The lipids were 737 
included in the ethanol stream and liposome formation was performed in a SHM, operated at 2mL min
-1
 and a ratio of 738 
1:3 solvent:aqueous solution. Protein was added post-liposome formation. OVA = ovalbumin, N/A = not applicable. 739 
 Liposome w/o OVA 
after SHM 
Liposome with OVA in 
collection vial 
Liposome with OVA after 
three passes through TFF
* 
Size (nm) 62.8 ± 1.9 88.5 ± 5.7 89.3 ± 10.9 
Polydispersity 0.44 ± 0.02 0.45 ± 0.008 0.42 ± 0.02 
Zeta potential (mV) 83.9 ± 3.5 43.6 ± 1.6 69.2 ± 6.1 
Loading (%) N/A N/A 23.9 ± 0.8 
Effec. ethanol (% v/v) N/A 15.0 ± 6.9 4.1 ± 1.5 
*
After each pass a volume of pure buffer was added to the retentate, keeping the level of liquid constant. 740 





